Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control

CNS Spectrums

Volumn 22, Issue 4, 2017, Pages 333-341

  Landbloom, Ronald ^a   MacKle, Mary ^a   Wu, Xiao ^b   Kelly, Linda ^a   Snow Adami, Linda ^a   McIntyre, Roger S ^c,d   Mathews, Maju ^e   Hundt, Carla ^e  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Jersey City ^*  (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Asenapine; efficacy; olanzapine; safety; schizophrenia

Indexed keywords

ASENAPINE; CREATINE KINASE; OLANZAPINE; PLACEBO; BENZODIAZEPINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV; DYSGEUSIA; EFFECTIVE DOSE (PHARMACOLOGY); EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERSOMNIA; HYPESTHESIA; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; WEIGHT CHANGE; WEIGHT GAIN; AKATHISIA, DRUG-INDUCED; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; EUROPE; EXTRAPYRAMIDAL SYNDROME; LEAST SQUARE ANALYSIS; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; DISEASE PROGRESSION; DISORDERS OF EXCESSIVE SOMNOLENCE; DIZZINESS; DOUBLE-BLIND METHOD; DYSGEUSIA; EUROPE; FEMALE; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; HYPESTHESIA; LEAST-SQUARES ANALYSIS; MALE; MOUTH DISEASES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84994634491     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852916000377     Document Type: Article

References (25)

1. Lora A, Kohn R, Levav I, McBain R, Morris J, Saxena S. Service availability and utilization and treatment gap for schizophrenic disorders: A survey in 50 low-A nd middle-income countries. Bulletin of the World Health Organization. 2012; 90(1): 47-54B.
2. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261-276.
3. Freedman R. Schizophrenia. N Engl J Med. 2003; 349: 1738-1749.
4. Smith T WC, Lieberman J. Schizophrenia (maintenance treatment). Am Fam Physician. 2010; 82(4): 338-339.
5. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts": What we know in 2008, part 1: Overview. Schizophr Res. 2008; 100(1-3): 4-19.
6. SAPHRIS [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2015.
7. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009; 23(1): 65-73.
8. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: A placebo-A nd risperidonecontrolled trial. J Clin Psychiatry. 2007; 68(10): 1492-1500.
9. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-A nd haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010; 30(2): 106-115.
10. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011; 72(3): 349-355.
11. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine vs olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010; 43(4): 138-146.
12. Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company; 1997.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology Rev ed. Rockville, MD: National Institutes of Mental Health; 1976.
14. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): The CGI-BP. Psychiatry Res. 1997; 73(3): 159-171.
15. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970; 212: 11-19.
16. Simpson GM, et al. Adverse effect measures. In: American Psychiatric Association. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000: 163-164.
17. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154(5): 672-676.
18. Barnes T. Adverse effect measures. In: American Psychiatric Association. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000: 165-166.
19. Guy W. Abnormal involuntary movement scale (AIMS). In: Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised 1976. Rockville, MD: National Institutes of Mental Health; 534-537.
20. Dunn OJ. Multiple comparisons among means. J Am Stat Assoc. 1961; 56(293): 52-64.
21. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988; 75(4): 800-802.
22. Mietinnen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985; 4(2): 213-226.
23. Kemp DE, Zhao J, Cazorla P, et al. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. J Clin Psychiatry. 2014; 75(3): 238-245.
24. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-610.
25. Kinon BJ, Liu-Seifert H, Adams DH, Citrome L. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. J Clin Psychopharmacol. 2006;26(6):632-637.